Search This Blog

Thursday, December 10, 2020

Uber asks U.S. states to prioritize its drivers for COVID-19 vaccine

 Uber Technologies Inc on Thursday sent letters to the governors of all U.S. states, asking for its ride-hail and food delivery drivers to get early access to COVID-19 vaccines as essential workers.

The company also said it will send a letter to U.S. President-elect Joe Biden.

The letters come less than a week after Uber sent a similar letter to a committee of the U.S. Centers for Disease Control and Prevention.

Uber Chief Executive Dara Khosrowshahi, in a letter seen by Reuters, urged Florida Governor Ron DeSantis to classify Uber’s workers as essential, entitled to vaccines immediately after healthcare professionals and long-term care facility residents.

“Over the last nine months, these workers have been a lifeline to their communities. They have transported healthcare workers to hospitals, delivered food to people socially distancing at home, and helped local restaurants stay in business,” the letter said.

Khosrowshahi also said Uber’s app could offer vaccination information to Americans.

With initial vaccine doses limited and strong federal guidance lacking, it has fallen to U.S. states to determine who will be first in line to be vaccinated. More than 20 large industries have urged public officials to prioritize their workers.

Uber said its U.S. drivers who have done at least three trips since the pandemic began in March stood at over 1.5 million.

Florida, where Uber has the most pandemic drivers at around 236,000, expects to receive vaccine doses for 500,000 to 1 million residents this month. The state has more than 1 million licensed healthcare professionals and some 146,000 long-term-care residents, according to state health department data.

U.S. officials have said if vaccines get approved quickly they will distribute enough doses to inoculate 20 million people by the end of the year, roughly covering all U.S. healthcare workers. Doses for some 100 million people are expected by the end of February.

https://www.reuters.com/article/health-coronavirus-uber-vaccine/uber-asks-u-s-states-to-prioritize-its-drivers-for-covid-19-vaccine-idUSKBN28K1VX

U.S. weekly jobless claims surge as COVID-19 infections spiral

 The number of Americans filing first-time claims for jobless benefits jumped to a near three-month high last week as mounting new COVID-19 infections caused more business restrictions, further evidence that the pandemic and lack of additional fiscal stimulus were hurting the economy.

The weekly unemployment claims report from the Labor Department on Thursday, the most timely data on the economy’s health, followed in the wake of data last week showing job gains in November were the smallest since the recovery started in May. Labor market distress is keeping inflation muted, with prices rising moderately in November, other data showed.

“Mass unemployment continues to weigh on economic growth and demand,” said Chris Rupkey, chief economist at MUFG in New York. “If Congress continues to sit on its hands without voting on a new relief package, the plight of the nation’s unemployed is going to grow darker by the hour.”

Initial claims for state unemployment benefits surged 137,000 to a seasonally adjusted 853,000 for the week ended Dec. 5, the highest since mid-September. The weekly increase was the largest since last March, when the nation was battered by the first wave of coronavirus infections.

Economists polled by Reuters had forecast 725,000 applications in the latest week.

Unadjusted claims vaulted 228,982 to 947,504 last week. Economists prefer the unadjusted number because of earlier difficulties adjusting the claims data for seasonal fluctuations due to the economic shock caused by the pandemic. Including a government-funded program for the self-employed, gig workers and others who do not qualify for the regular state unemployment programs, 1.4 million people filed claims last week.

The United States is in the throes of a fresh wave of coronavirus infections, with the number of confirmed cases crossing the 15 million mark on Tuesday. New strict stay-at-home orders went into effect in California earlier this week, affecting about three-quarters of the nearly 40 million people in the nation’s most-populous state.

Other states and local governments have also imposed restrictions on businesses, which economists expect to lead to a fresh round of layoffs during winter, especially without additional pandemic relief money from the government.

More than $3 trillion in government pandemic relief agreed earlier this year helped millions of unemployed Americans cover daily expenses and companies keep workers on payrolls. The fiscal stimulus has almost dried up.

A deal on another rescue package remained elusive on Wednesday, with Senate Majority Leader Mitch McConnell saying Congress was still looking for a way forward.

U.S. stocks opened lower. The dollar fell against a basket of currencies. U.S. Treasury prices rose.

TAME INFLATION

The claims report also showed the number of people receiving benefits after an initial week of aid increased 230,000 to 5.757 million in the week ended Nov. 28. That was the first increase since August. The so-called continuing claims had been pushed down in part by people exhausting their eligibility for benefits, limited to 26 weeks in most states.

At least 4.533 million people were on extended benefits during the week ending Nov. 21. These benefits, which are funded by the government, are set to expire on Dec. 26, if Congress does not reach a deal on another round of stimulus.

Just over 19 million people were receiving benefits under all programs during that period.

Though a government watchdog found the claims data is inaccurate because of people filing multiple claims, processing backlogs and fraud, it is broadly in line with other labor market data that have suggested a slowing in the recovery after a burst of hiring during the summer.

Jobless claims hit a record 6.867 million in March. They have been stuck above their 665,000 peak during the 2007-09 Great Recession. The economy created 245,000 jobs in November, the fifth straight monthly slowdown in employment growth. Only 12.4 million of the 22.2 million jobs lost in March and April have been recovered.

In a separate report on Thursday, the Labor Department said its consumer price index rose 0.2% in November after being unchanged in October. In the 12 months through November, CPI increased 1.2% after a similar gain in October.

Economists had forecast the CPI edging up 0.1% in November and rising 1.1% year-on-year. There was a broad increase in prices last month, though food was slightly cheaper.

Excluding the volatile food and energy components, the CPI also increased 0.2% after being flat in October.

Owners’ equivalent rent of primary residence, which is what a homeowner would pay to rent or receive from renting a home, was unchanged after rising 0.2% the prior month. Rent inflation has been tamed by forbearance agreements between tenants and landlords and a government moratorium on evictions.

The cost of healthcare dipped 0.1% after declining 0.4% in October. In the 12 months through November, the so-called core CPI advanced 1.6%, matching October’s increase.

The Federal Reserve’s preferred inflation measure, the core personal consumption expenditures (PCE) price index increased 1.4% in the 12 months through October. The central bank has a 2% target, a flexible average. November’s core PCE price index data is scheduled to be released later this month.

https://www.reuters.com/article/usa-economy/u-s-weekly-jobless-claims-surge-as-covid-19-infections-spiral-idUSKBN28K1RS

AbbVie: Rinvoq achieved superiority v. Dupixent in atopic dermatitis study

 

  • AbbVie (ABBV -1.0%) has reported top-line data from Phase 3b Heads Up study, evaluating its Rinvoq (upadacitinib) versus Sanofi / Regeneron's Dupixent (dupilumab), in adults with atopic dermatitis.
  • Safety profile of upadacitinib was consistent with previous atopic dermatitis studies, with no new safety risks observed
  • 71% of the patients in upadacitinib arm achieved 75% improvement in eczema severity index at week 16 (primary endpoint), compared to 61% of dupilumab-treated patients.
  • Additionally, upadacitinib also showed superiority compared to dupilumab for all ranked secondary endpoints, including in early improvements of itch and skin clearance.
  • Full results from the study will be submitted for publication in a peer-reviewed journal.
  • Yesterday, the company announced that upadacitinib topped placebo at helping previously untreated ulcerative colitis patients achieve remission by the eight-week mark. 26% of the patients in Rinvoq arm hit that benchmark, versus just 5% on placebo.
  • https://seekingalpha.com/news/3643327-abbvie-says-rinvoq-achieved-superiority-versus-dupixent-in-atopic-dermatitis-study

FDA Panel reviewing Pfizer/ BioNTech COVID-19 vaccine

 

U.S. nears final COVID vaccine review as daily national deaths top 3,250

 The United States on Wednesday crossed an ominous new threshold of more than 3,250 lives lost to COVID-19 in a single day while public health officials stepped up preparations for a vaccine campaign of historic scope ahead of final regulatory review.

Steady movement toward a vaccine rollout on the eve of a critical review by leading U.S. medical experts comes as COVID-19 caseloads surged alarmingly higher, straining healthcare systems in some pandemic hot spots to the breaking point.

Intensive care units at hundreds of hospitals in cities and rural communities across the country were reported to be at or near capacity, U.S. Department of Health and Human Services data showed.

Ten mostly rural counties scattered across California reported having no ICU beds whatsoever on Wednesday, according to state health figures analyzed by Reuters. In Fresno County, home to 1 million people, only seven ICU beds remained unfilled on Wednesday. Largely agricultural San Joaquin County just to the north was down to just five ICU beds.

The number of COVID patients hospitalized nationwide grew to a new all-time high of 106,217 by late Wednesday, up some 18% over the previous two weeks.

The United States also has documented an average of 2,259 deaths and 205,661 new infections each day over the past week, a toll that U.S. health officials warn is likely to accelerate in the coming months before a vaccine becomes widely available to the public.

At least 3,253 U.S. patients perished on Wednesday alone, according to a Reuters tally of state-by-state data.

The latest figure surpassed the previous Dec. 3 record of 2,861 COVID deaths and marked the first time the virus has claimed 3,000 American lives or more in a single day - exceeding the death toll from the Sept. 11, 2001, attacks on America by suicide hijackers.

To date, the highly contagious respiratory illness has killed more than 289,000 Americans, out some 15 million known to have been infected since January.

Medical experts have said the crisis will only worsen in the weeks ahead amid colder weather, especially if Americans continue to disregard warnings to avoid unnecessary travel and large gatherings over the holidays.

Besides the monumental human cost, the pandemic has wreaked havoc on the economy, forcing millions out of work as public health authorities imposed sweeping restrictions on social and economic life in an effort to tamp down the contagion.

Congress, meanwhile, has struggled to end a months-long political stalemate over an economic assistance.

The Democratic-controlled U.S. House of Representatives on Wednesday approved a one-week extension of federal government funding, giving lawmakers more time to haggle over a broader spending package with coronavirus relief.

The Republican-led Senate was expected to vote on the measure as early as Thursday and send it to President Donald Trump in time to avoid a government shutdown.

But disagreements remain over business liability protections demanded by Republicans and aid to state and local governments sought by Democrats before a final deal is reached on economic assistance.

VACCINES ON THE WAY

Offering a new glimmer of hope, some officials said vaccinations could begin as soon as this weekend, and states have escalated plans for what is likely to be distribution effort of unprecedented dimensions.

“I can’t think of a government operation that has been commenced that is more difficult and intricate than what governments will be asked to do here,” New York Governor Andrew Cuomo said at a briefing on Wednesday.

A panel of independent medical experts was due meet on Thursday to decide whether to recommend that a vaccine from Pfizer Inc and German partner BioNTech SE. should receive emergency use authorization of the U.S. Food and Drug Administration.

In a sign that approval could be swift, documents released by the FDA ahead of the advisory review raised no new red flags over the safety or efficacy of the Pfizer vaccine.

FDA consent could come as early as Friday or Saturday, followed by the first U.S. injections on Sunday or Monday, Moncef Slaoui, chief adviser to the Trump administration’s Operation Warp Speed vaccine development program, told Fox News on Tuesday.

Britain became the first Western nation to begin mass inoculations with the Pfizer vaccine on Tuesday. Canada on Wednesday approved the same vaccine after an accelerated review process.

The United States is in dire need of a new mechanism for fighting the pandemic, given that so many Americans have refused to follow guidance for wearing face coverings and keeping their distance for people beyond their own households.

Medical experts expect yet another surge of infections and hospitalizations following year-end holiday gatherings, even as initial batches of vaccine are be administered to high-priority recipients, including healthcare workers and nursing home residents.

U.S. Health and Human Services Secretary Alex Azar told “CBS This Morning” he expected inoculations to be reaching the general public in February, March and April, with enough vaccine supply “for all Americans” during the second quarter of next year.

Still, a sizable percentage of the U.S. population has expressed skepticism about getting a COVID-19 vaccine, creating an additional challenge.

Biden set a goal of vaccinating 100 million people - nearly a third of the U.S. population, within the first 100 days of his administration, or by April 29.

https://www.reuters.com/article/us-health-coronavirus-usa/u-s-nears-final-covid-vaccine-review-as-daily-national-deaths-top-3250-idUSKBN28I1WD

Editas Medicine submits IND application for EDIT-301

 

  • Editas Medicine (NASDAQ:EDIT) has submitted an Investigational New Drug (IND) application with the FDA for the initiation of a Phase 1/2 clinical trial of EDIT-301, an experimental CRISPR/Cas12a gene editing medicine in development for the treatment of sickle cell disease.
  • The Company previously received Rare Pediatric Disease designation from the FDA for EDIT-301.
  • Sickle cell disease is caused by a mutation in the beta-globin gene that leads to polymerization of the sickle hemoglobin protein
  • https://seekingalpha.com/news/3643158-editas-medicine-submits-ind-application-for-editminus-301

Biogen files new drug application for aducanumab in Japan